secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001193125-26-197124
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax Q1 revenue up 224% to $64.9M; net loss narrows to $42.7M from $84.8M
---------------------------------------------------------------------------

- Revuforj net revenue $48.9M (+144% YoY, +11% QoQ); total prescriptions up ~160% YoY.
- Niktimvo net revenue $55.1M; Syndax collaboration revenue $15.9M (50% of profit share).
- Net loss $0.48/share vs $0.98/share prior year; cash and investments $352.1M.
- FY2026 opex guidance ~$400M (excl. $50M stock comp); expects to reach profitability.
- Topline data from Phase 2 axatilimab trials in IPF and frontline chronic GVHD expected Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000119312526197124/0001193125-26-197124-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000119312526197124/sndx-20260430.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-197124

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer